Table 1.
Agents targeting TGF-β signaling pathway.
| Classification | Agent | Target | Company/Authors |
|---|---|---|---|
| Antibody | Fresolimumab | TGF-β1/2 | Genzyme |
| SRK181 | TGF-β1 | Scholar Rock | |
| LY3022859 | TGFβRII | Eli Lilly | |
| 264RAD | Integrin αvβ6 | AstraZeneca | |
| 1D11 | TGF-β1/2/3 | Genzyme | |
| 2G7 | TGF-β1/2/3 | Genentech | |
| YM101 | TGF-β1/2/3 and PD-L1 | YZY Biopharma | |
| Receptor kinase inhibitor | Vactosertib | TGFβRI | MedPacto |
| Galunisertib | TGFβRI | Eli Lilly | |
| LY3200882 | TGFβRI | Eli Lilly | |
| LY573636 | TGFβRI | Eli Lilly | |
| LY2109761 | TGFβRI/II | Eli Lilly | |
| SB-431542 | TGFβRI | GlaxoSmithKline | |
| SB-505124 | TGFβRI | GlaxoSmithKline | |
| IN-1130 | TGFβRI | In2Gen | |
| Trap | AVID200 | TGF-β1/3 | Forbius |
| Luspatercept | TGF-β1/2/3 | Acceleron | |
| M7824 | TGF-β1/2/3 and PD-L1 | Merck KGaA | |
| SHR-1701 | TGF-β1/2/3 and PD-L1 | Hengrui | |
| Antisense oligonucleotides | AP 12009 | TGF-β2 | Antisense Pharma |
| AP 11014 | TGF-β1 | Antisense Pharma | |
| Cancer vaccine | Vigil | TGF-β1/2 | Gradalis |
| Lucanix | TGF-β2 | NovaRx |